Literature DB >> 7146447

Pediatric Candida albicans arthritis: case report of hip involvement with a review of the literature.

T L Pope.   

Abstract

Candida albicans arthritis in the pediatric patient is rarely reported. In each instance, the patient has had one of the factors that predispose to fungal sepsis: broad spectrum antibiotic therapy, hyperalimentation, prematurity, abdominal surgery, corticosteroid or immunosuppressive therapy, malnutrition, maternal vaginal candidiasis, or lymphoproliferative disorders. To avoid the potentially fatal consequences of delayed treatment, early recognition of the disease is imperative. The patient usually refuses to use the affected joint and plain radiography shows a joint effusion with soft tissue swelling. Osteomyelitis develops in approximately half of the cases. Arthrocentesis with fungal cultures is the best method to make the diagnosis. Treatment is primarily chemotherapeutic and the drug of choice is the membrane inhibitor amphotericin B given intravenously. The antimetabolite 5-fluorocytosine is a second-line drug to be used if resistance develops. All cases before the present one involved the knee joint initially. The case presented involved the left hip and was successfully treated with intravenous amphotericin B.

Entities:  

Mesh:

Year:  1982        PMID: 7146447

Source DB:  PubMed          Journal:  Prog Pediatr Surg        ISSN: 0079-6654


  2 in total

Review 1.  Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review.

Authors:  J Evdoridou; E Roilides; E Bibashi; G Kremenopoulos
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

2.  Candida Arthritis: Analysis of 112 Pediatric and Adult Cases.

Authors:  Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Nikolaos V Sipsas; Brad Moriyama; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Saad J Taj-Aldeen; Andy O Miller; Ruta Petraitiene; Olivier Lortholary; Thomas J Walsh
Journal:  Open Forum Infect Dis       Date:  2015-12-23       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.